Skip to content

Author

Ke-Xuan Bao

1 paper indexed here

We haven’t gathered this author’s papers yet. Follow them and we’ll fetch their work.

Not the right person? Other researchers publish under this name.

Review Nov 2026

Beyond ACE2 downregulation: daphnetin as a multi-target agent for COVID-19 and rheumatic comorbidities.

The continuous emergence of SARS-CoV-2 variants (e.g., JN.1, KP.3) and the significantly elevated risk of severe COVID-19 in patients with rheumatic autoimmune diseases highlight an urgent unmet clinical need for dual-targeted therapeutics. Daphnetin (7,8-dihydroxycoumarin), a natural coumarin compound with a long hist...

Meng Chen, Nan-Nan Zhang, Qiong Wu et al. · 0 citations

We use cookies to run the site and, with your consent, for analytics and to show ads. See our Cookie Policy.